ClinicalTrials.gg

Program

AEF0217

A development code. Also written as “AEF0217 100 µg” and “AEF0217 300 µg”.

Its studies are mostly in Down Syndrome, led by Aelis Farma.

Furthest: phase 2, since Jan 11, 20233 company-led studies, 1 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aelis Farma31 open or runningphase 2since Jan 11, 2023Dec 7, 2021Dec 31, 2027phase 2 · NCT07334912

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 7, 2021First study: phase 1 study in Safety, Tolerability, Pharmacokinetics of AEF0217First studyNCT05170737 · 68 enrolled · Spain
  2. Jan 11, 2023Phase 2 study in Down SyndromeNCT05748405 · 40 enrolled · Spain
  3. Nov 20, 2025Phase 2 study in Down SyndromeNCT07334912 · 188 planned · France, Italy, Spain

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Down SyndromeNCT07334912

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07334912Down Syndrome · France, Italy, Spain2RecruitingDec 31, 2027188
NCT05748405Down Syndrome · Spain2CompletedOct 7, 202440
NCT05170737Safety, Tolerability, Pharmacokinetics of AEF0217 · Spain1CompletedJun 28, 202268

How it is read

Names in the registry

  • “AEF0217”, 2 entries
  • “AEF0217 100 µg”, 1 entry
  • “AEF0217 300 µg”, 1 entry

Codes read as this program: AEF0217.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.